These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36114129)

  • 1. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naïve adults.
    Diemert DJ; Zumer M; Campbell D; Grahek S; Li G; Peng J; Elena Bottazzi M; Hotez P; Bethony J
    Vaccine; 2022 Oct; 40(42):6084-6092. PubMed ID: 36114129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial.
    Zinsou JF; Diemert DJ; Dejon-Agobé JC; Adégbité BR; Honkpehedji YJ; Vodonou KG; Bikangui R; Edoa JR; Massinga Loembe M; Li G; Yazdanbakhsh M; Bottazzi ME; van Leeuwen R; Kremsner PG; Hotez PJ; Bethony JM; Grobusch MP; Adegnika AA
    Lancet Infect Dis; 2024 Jul; 24(7):760-774. PubMed ID: 38513684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial.
    Adegnika AA; de Vries SG; Zinsou FJ; Honkepehedji YJ; Dejon Agobé JC; Vodonou KG; Bikangui R; Bouyoukou Hounkpatin A; Bache EB; Massinga Loembe M; van Leeuwen R; Molemans M; Kremsner PG; Yazdanbakhsh M; Hotez PJ; Bottazzi ME; Li G; Bethony JM; Diemert DJ; Grobusch MP;
    Lancet Infect Dis; 2021 Feb; 21(2):275-285. PubMed ID: 32926834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults.
    Diemert DJ; Freire J; Valente V; Fraga CG; Talles F; Grahek S; Campbell D; Jariwala A; Periago MV; Enk M; Gazzinelli MF; Bottazzi ME; Hamilton R; Brelsford J; Yakovleva A; Li G; Peng J; Correa-Oliveira R; Hotez P; Bethony J
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005574. PubMed ID: 28464026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74.
    Pearson MS; Jariwala AR; Abbenante G; Plieskatt J; Wilson D; Bottazzi ME; Hotez PJ; Keegan B; Bethony JM; Loukas A
    Hum Vaccin Immunother; 2015; 11(5):1251-7. PubMed ID: 26018444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a peptide vaccine against hookworm infection: Immunogenicity, efficacy, and immune correlates of protection.
    Shalash AO; Becker L; Yang J; Giacomin P; Pearson M; Hussein WM; Loukas A; Toth I; Skwarczynski M
    J Allergy Clin Immunol; 2022 Jul; 150(1):157-169.e10. PubMed ID: 35278494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine.
    Seid CA; Curti E; Jones RM; Hudspeth E; Rezende W; Pollet J; Center L; Versteeg L; Pritchard S; Musiychuk K; Yusibov V; Hotez PJ; Bottazzi ME
    Hum Vaccin Immunother; 2015; 11(6):1474-88. PubMed ID: 25905574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon.
    Mouwenda YD; Betouke Ongwe ME; Sonnet F; Stam KA; Labuda LA; De Vries S; Grobusch MP; Zinsou FJ; Honkpehedji YJ; Dejon Agobe JC; Diemert DJ; van Leeuwen R; Bottazzi ME; Hotez PJ; Kremsner PG; Bethony JM; Jochems SP; Adegnika AA; Massinga Loembe M; Yazdanbakhsh M
    PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009732. PubMed ID: 34597297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection.
    Pearson MS; Bethony JM; Pickering DA; de Oliveira LM; Jariwala A; Santiago H; Miles AP; Zhan B; Jiang D; Ranjit N; Mulvenna J; Tribolet L; Plieskatt J; Smith T; Bottazzi ME; Jones K; Keegan B; Hotez PJ; Loukas A
    FASEB J; 2009 Sep; 23(9):3007-19. PubMed ID: 19380510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of urinary metabolomics in a phase I hookworm vaccine trial in Gabon.
    Betouke Ongwe ME; Mouwenda YD; Stam KA; Kremsner PG; Lell B; Diemert D; Bethony J; Bottazzi ME; Hotez PJ; Leeuwen RV; Grobusch MP; Adegnika AA; Mayboroda OA; Yazdanbakhsh M
    PLoS One; 2022; 17(9):e0275013. PubMed ID: 36155987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area.
    Diemert DJ; Correa-Oliveira R; Fraga CG; Talles F; Silva MR; Patel SM; Galbiati S; Kennedy JK; Lundeen JS; Gazzinelli MF; Li G; Hoeweler L; Deye GA; Bottazzi ME; Hotez PJ; El Sahly HM; Keitel WA; Bethony J; Atmar RL
    PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011236. PubMed ID: 36996185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis.
    Pearson MS; Pickering DA; Tribolet L; Cooper L; Mulvenna J; Oliveira LM; Bethony JM; Hotez PJ; Loukas A
    J Infect Dis; 2010 May; 201(10):1561-9. PubMed ID: 20367477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults.
    Bethony JM; Simon G; Diemert DJ; Parenti D; Desrosiers A; Schuck S; Fujiwara R; Santiago H; Hotez PJ
    Vaccine; 2008 May; 26(19):2408-17. PubMed ID: 18396361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area.
    Keitel WA; Potter GE; Diemert D; Bethony J; El Sahly HM; Kennedy JK; Patel SM; Plieskatt JL; Jones W; Deye G; Bottazzi ME; Hotez PJ; Atmar RL
    Vaccine; 2019 Oct; 37(43):6500-6509. PubMed ID: 31515141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
    Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
    Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine.
    Brelsford JB; Plieskatt JL; Yakovleva A; Jariwala A; Keegan BP; Peng J; Xia P; Li G; Campbell D; Periago MV; Correa-Oliveira R; Bottazzi ME; Hotez PJ; Diemert D; Bethony JM
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005385. PubMed ID: 28192438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths.
    Diemert DJ; Pinto AG; Freire J; Jariwala A; Santiago H; Hamilton RG; Periago MV; Loukas A; Tribolet L; Mulvenna J; Correa-Oliveira R; Hotez PJ; Bethony JM
    J Allergy Clin Immunol; 2012 Jul; 130(1):169-76.e6. PubMed ID: 22633322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.